Real‐life second‐line epirubicin–paclitaxel regimen as treatment of relapsed small‐cell lung cancer: EpiTax study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Real‐life second‐line epirubicin–paclitaxel regimen as treatment of relapsed small‐cell lung cancer: EpiTax study

Published:2022-08-24 Issue:3 Volume:12 Page:2658-2665
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Medicine

Author:

Annic Josselin¹,Babey Hélène¹,Corre Romain²,Descourt Renaud¹,Quéré Gilles¹,Renaud Emmanuelle¹,Lambert Mickaël¹,Le Noac'h Pierre¹,Dhamelincourt Estelle¹,Nguyen Jessica¹,Vu Alicia³,Bourbonne Vincent³⁴,Robinet Gilles¹,Geier Margaux¹^ORCID

Affiliation:

1. Department of Medical Oncology, CHRU Morvan University Hospital Brest France

2. Department of Pulmonary Diseases CH Cornouaille Quimper France

3. Department of Radiation Oncology University Hospital Brest France

4. LaTIM UMR 1101 INSERM University Brest Brest France

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.5143

Reference25 articles.

1. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group.

2. Treatment of Brain Metastases of Small-Cell Lung Cancer: Comparing Teniposide and Teniposide With Whole-Brain Radiotherapy—A Phase III Study of the European Organization for the Research and Treatment of Cancer Lung Cancer Cooperative Group

3. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer

4. Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

5. Validation of standard definition of sensitive versus refractory relapsed small cell lung cancer: A pooled analysis of topotecan second-line trials

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ITGB4 Serves as an Identification and Prognosis Marker Associated with Immune Infiltration in Small Cell Lung Carcinoma;Molecular Biotechnology;2023-10-17

2. Entinostat Enhances the Efficacy of Chemotherapy in Small Cell Lung Cancer Through S-phase Arrest and Decreased Base Excision Repair;Clinical Cancer Research;2023-09-19

3. Mechanism of Taxanes in the Treatment of Lung Cancer Based on Network Pharmacology and Molecular Docking;Current Issues in Molecular Biology;2023-08-07

4. Chemotherapeutic and targeted drugs-induced immunogenic cell death in cancer models and antitumor therapy: An update review;Frontiers in Pharmacology;2023-04-21

5. Epirubicin/paclitaxel;Reactions Weekly;2023-03-18

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3